Fluorouracil

Generic Name
Fluorouracil
Brand Names
Actikerall, Carac, Efudex, Fluoroplex, Tolak
Drug Type
Small Molecule
Chemical Formula
C4H3FN2O2
CAS Number
51-21-8
Unique Ingredient Identifier
U3P01618RT
Background

A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.

Indication

For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including ...

Associated Conditions
Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis
Associated Therapies
-

Intraoperative 5-fluorouracil Augmentation of Trabeculectomy

First Posted Date
2024-12-20
Last Posted Date
2024-12-20
Lead Sponsor
Moorfields Eye Hospital NHS Foundation Trust
Target Recruit Count
368
Registration Number
NCT06745856

First-line Treatment with RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)

First Posted Date
2024-12-12
Last Posted Date
2024-12-12
Lead Sponsor
Qilu Hospital of Shandong University
Target Recruit Count
110
Registration Number
NCT06730373
Locations
🇨🇳

The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China

🇨🇳

Binzhou Medical University Hospital, Binzhou, Shandong, China

🇨🇳

Shengli Oilfield Central Hospital, Dongying, Shandong, China

and more 16 locations

Carac & PDT Combination in the Treatment Of Actinic Keratoses

First Posted Date
2024-12-02
Last Posted Date
2024-12-02
Lead Sponsor
Skin Laser & Surgery Specialists
Target Recruit Count
60
Registration Number
NCT06712381

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

First Posted Date
2024-10-29
Last Posted Date
2024-12-18
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
1000
Registration Number
NCT06662786
Locations
🇲🇾

Hospital Pulau Pinang, Georgetown, Malaysia

🇲🇾

Hospital Umum Sarawak, Kuching, Malaysia

🇲🇾

Hospital Raja Permaisuri Bainun, Ipoh, Malaysia

and more 20 locations

Hepatic Arterial Infusion Chemotherapy With Lipiodol Embolization in Advanced Hepatocellular Carcinoma

First Posted Date
2024-10-09
Last Posted Date
2024-10-09
Lead Sponsor
National Taiwan University Hospital
Target Recruit Count
24
Registration Number
NCT06632717
Locations
🇨🇳

National Taiwan University Hospital, Taipei, Taiwan

© Copyright 2024. All Rights Reserved by MedPath